全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Urachal Cancer: Experience of a High-Volume Bladder Cancer Center

DOI: 10.4236/oju.2023.137025, PP. 201-213

Keywords: Urachal Cancer, Urachus, Bladder Cancer

Full-Text   Cite this paper   Add to My Lib

Abstract:

Introduction: Primary urachal cancer (UrCa) is rare, with an estimated incidence of 0.2% - 0.5% of all bladder tumors. Although the preferred treatment is surgical, there is no consensus on the best approach. We present our experience managing 14 cases of primary UrCa. Methods: A retrospective analysis was conducted on the clinical records of a high-volume bladder cancer center in the UK to identify patients diagnosed with UrCa between May 2013 and June 2022. Results: 9 males and 6 females, aged between 30 and 85 years, were included. The diagnosis was most commonly made via flexible cystoscopy and CT for haematuria. 3 patients had metastasis at presentation, and while radiologically no patients showed positive lymph nodes, 2 patients were found to have positive lymph nodes on histopathology. 13 patients underwent partial cystectomy, with 1 undergoing radical cystoprostatectomy. 8 patients underwent concurrent umbilectomy and/or lymphadenectomy. The most common histological subtype was mucinous adenocarcinoma. 2 patients experienced local recurrence and underwent transurethral resection, while 6 patients experienced metastasis. Metastasis-free survival rate was 74.1% and 55.6% at 12 and 24 months, respectively. Umbilectomy and lymphadenectomy did not decrease rates of positive surgical margin, local recurrence, metastasis, or mortality. Conclusions: UrCa is a rare and aggressive malignancy that can occur at any age and may be advanced upon presentation. Bladder-sparing surgery is becoming more prevalent, with chemotherapy being reserved for recurrence or metastasis. In our series, routine umbilectomy and lymphadenectomy did not improve oncologic outcomes. However, lymphadenectomy may have a role in cancer staging.

References

[1]  Ding, L., Xia, B., Zhang, Y., Liu, Z. and Wang, J. (2022) Web-Based Prediction Models for Overall Survival and Cancer-Specific Survival of Patients with Primary Urachal Carcinoma: A Study Based on SEER Database. Frontiers in Public Health, 10, Article ID: 870920.
https://doi.org/10.3389/fpubh.2022.870920
[2]  Mylonas, K.S., O’Malley, P., Ziogas, I.A., El-Kabab, L. and Nasioudis, D. (2017) Malignant Urachal Neoplasms: A Population-Based Study and Systematic Review of Literature. Urologic Oncology: Seminars and Original Investigations, 35, 33.e11-33.e19.
https://doi.org/10.1016/j.urolonc.2016.07.021
[3]  Chen, D., Li, Y., Yu, Z., et al. (2014) Investigating Urachal Carcinoma for More than 15 Years. Oncology Letters, 8, 2279-2283.
https://doi.org/10.3892/ol.2014.2502
[4]  Dursun, F., Lim, K., Svatek, R.S., et al. (2022) Clinical Outcomes and Patterns of Population-Based Management of Urachal Carcinoma of the Bladder: An Analysis of the National Cancer Database. Cancer Medicine, 11, 4273-4282.
[5]  Szarvas, T., Módos, O., Niedworok, C., et al. (2016) Clinical, Prognostic, and Therapeutic Aspects of Urachal Carcinoma—A Comprehensive Review with Meta-Analysis of 1,010 Cases. Urologic Oncology: Seminars and Original Investigations, 34, 388-398.
https://doi.org/10.1016/j.urolonc.2016.04.012
[6]  Bruins, H.M., Visser, O., Ploeg, M., Hulsbergen-Van De Kaa, C., Kiemeney, L.A.L.M. and Witjes, J.A. (2012) The Clinical Epidemiology of Urachal Carcinoma: Results of a Large, Population Based Study. Journal of Urology, 188, 1102-1107.
https://doi.org/10.1016/j.juro.2012.06.020
[7]  Jia, Z., Chang, X., Li, X., Wang, B. and Zhang, X. (2020) Urachal Carcinoma: Are Lymphadenectomy and Umbilectomy Necessary? Medical Science Monitor, 26, e927913.
https://doi.org/10.12659/MSM.927913
[8]  Ashley, R.A., Inman, B.A., Sebo, T.J., et al. (2006) Urachal Carcinoma: Clinicopathologic Features and Long-Term Outcomes of an Aggressive Malignancy. Cancer, 107, 712-720.
https://doi.org/10.1002/cncr.22060
[9]  Duan, F., Zhai, W., Zhang, B. and Guo, S. (2020) Urachal Carcinoma: Impact of Recurrence Pattern and Lymphadenectomy on Long-Term Outcomes. Cancer Medicine, 9, 4166-4174.
https://doi.org/10.1002/cam4.3059
[10]  Pinthus, J.H., Haddad, R., Trachtenberg, J., et al. (2006) Population Based Survival Data on Urachal Tumors. Journal of Urology, 175, 2042-2047.
https://doi.org/10.1016/S0022-5347(06)00263-1
[11]  Hayashi, T., Yuasa, T., Uehara, S., et al. (2016) Clinical Outcome of Urachal Cancer in Japanese Patients. International Journal of Clinical Oncology, 21, 133-138.
https://doi.org/10.1007/s10147-015-0866-8
[12]  NCCN (2021) Guidelines in Oncology (NCCN Guidelines). Bladder Cancer.
[13]  Grothey, A., Sobrero, A.F., Shields, A.F., et al. (2018) Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. New England Journal of Medicine, 378, 1177-1188.
https://doi.org/10.1056/NEJMoa1713709
[14]  Flammia, R.S., et al. (2022) Survival Benefit of Chemotherapy in a Contemporary Cohort of Metastatic Urachal Carcinoma. Urologic Oncology, 40, 165.e9-165.e15.
https://doi.org/10.1016/j.urolonc.2021.09.008

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133